GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Conmed Corp (NYSE:CNMD) » Definitions » Cash Flow from Financing

Conmed (Conmed) Cash Flow from Financing : $-110 Mil (TTM As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is Conmed Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Conmed paid $0 Mil more to buy back shares than it received from issuing new shares. It spent $40 Mil paying down its debt. It paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent $6 Mil paying cash dividends to shareholders. It spent $13 Mil on other financial activities. In all, Conmed spent $59 Mil on financial activities for the three months ended in Dec. 2023.


Conmed Cash Flow from Financing Historical Data

The historical data trend for Conmed's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conmed Cash Flow from Financing Chart

Conmed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 300.88 -52.06 -101.55 225.00 -110.43

Conmed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.52 5.35 -19.79 -37.23 -58.77

Conmed Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Conmed's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Conmed's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-110 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Conmed  (NYSE:CNMD) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Conmed's issuance of stock for the three months ended in Dec. 2023 was $0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Conmed's repurchase of stock for the three months ended in Dec. 2023 was $0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Conmed's net issuance of debt for the three months ended in Dec. 2023 was $-40 Mil. Conmed spent $40 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Conmed's net issuance of preferred for the three months ended in Dec. 2023 was $0 Mil. Conmed paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Conmed's cash flow for dividends for the three months ended in Dec. 2023 was $-6 Mil. Conmed spent $6 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Conmed's other financing for the three months ended in Dec. 2023 was $-13 Mil. Conmed spent $13 Mil on other financial activities.


Conmed Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Conmed's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Conmed (Conmed) Business Description

Traded in Other Exchanges
Address
11311 Concept Boulevard, Largo, FL, USA, 33773
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgery. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.
Executives
Peters Stanley W Iii officer: VP GM General Surgery C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Todd W. Garner officer: Executive Vice President & CFO C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Edward A. Clifford officer: VP Global Manufacturing C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Curt R Hartman director C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
John D. Ferrell officer: Executive Vice President - HR C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Brian Concannon director HAEMONETICS CORP, 400 WOOD RD, BRAINTREE MA 02184-9144
Peter K Shagory officer: EVP,STRAT & CORP DEVT C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Daniel Jonas officer: Vice President/Legal Affairs, other: General Counsel C/O CONMED CORP, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Terence M Berge officer: VP Corp. Treasurer C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Johonna Marie Pelletier officer: Treasurer and VP, Tax C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Jerome J. Lande director 1 WORLD TRADE CENTER, 85TH FLOOR, NEW YORK NY 10007
Brent Lalomia officer: Vice President QA and RA C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
John Jed Kennedy officer: VP GM GI C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Mark E Tryniski director C/O CONMED CORP., 11311 CONCEPT BOULEVARD, LARGO FL 33773
Pat Beyer officer: President-Conmed International C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773